A family with an astonishing rate of Alzheimer’s disease may harbor a powerful new gene. Post navigationPreviousPrevious post:Biohaven and Alzheimer’s Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate AD.NextNext post:Big data in Alzheimer’s: Are women more vulnerable to Alzheimer’s disease than men?
